Bio-Techne Corporation (NASDAQ: TECH) saw its shares surge 9.28% in Wednesday's pre-market trading following the company's impressive second-quarter fiscal 2025 earnings report. The life sciences company's strong financial performance, driven by robust growth in its core Protein Sciences segment, fueled investor optimism and propelled the stock higher.

For the quarter ended December 31, 2024, Bio-Techne reported adjusted earnings per share (EPS) of $0.42, surpassing the analyst consensus estimate of $0.39 by 7.69%. The company's quarterly sales of $297 million also exceeded the analyst consensus estimate of $285.7 million, representing an 8.96% year-over-year increase.

The company's strong Q2 results were underpinned by improving demand conditions in the biotech and biopharma markets, which had experienced reduced spending in the past two years. Bio-Techne's Protein Sciences segment, which develops and manufactures biological compounds for research, diagnostics, and cell and gene therapy development, witnessed a 7% year-over-year increase in sales to $211.6 million. This growth was a significant contributor to the company's overall revenue beat and reflected the growing popularity and adoption of its innovative products and services.